1,064 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
JNJ Johnson & Johnson $139.96 $375.48B N/A
Article Searches
Big Pharma's Showdown With Congress Over Drug Pricing: What It Really Means for You https://www.fool.com/investing/2019/02/27/big-pharmas-showdown-with-congress-over-drug-prici.aspx?source=iedfolrf0000001 Feb 27, 2019 - A Senate committee roasted top executives of the biggest drugmakers. But will anything change for ordinary Americans?
Theravance (TBPH) Q4 Loss Narrows, Revenues Beat Estimates http://www.zacks.com/stock/news/357180/theravance-tbph-q4-loss-narrows-revenues-beat-estimates?cid=CS-ZC-FT-357180 Feb 27, 2019 - Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q4. The top line surpasses estimates.
Chardan bullish on MeiraGTx after JNJ investment; shares up 14% https://seekingalpha.com/news/3437840-chardan-bullish-meiragtx-jnj-investment-shares-14-percent?source=feed_news_all Feb 27, 2019 - Chardan Capital Markets reiterates its Buy rating on gene therapy developer MeiraGTx (MGTX +14.4%) with a more bullish price target of $40 (165% upside) (from $30) after it announced a stake by a grou
Congress Grills Drugmakers: 5 Key Takeaways https://www.fool.com/investing/2019/02/26/congress-grills-drugmakers-5-key-takeaways.aspx?source=iedfolrf0000001 Feb 26, 2019 - Top drug companies addressed sky-high drug prices on Capitol Hill today.
What's in the Cards for Perrigo (PRGO) This Earnings Season? http://www.zacks.com/stock/news/356476/whats-in-the-cards-for-perrigo-prgo-this-earnings-season?cid=CS-ZC-FT-356476 Feb 22, 2019 - Perrigo (PRGO) is focused on Consumer Healthcare Americas segment. Let's see if it aids the company's results in the soon-to-be reported quarter.
Johnson & Johnson Is Subpoenaed for Talc Safety Information https://www.wsj.com/articles/doj-sec-subpoena-j-j-for-talc-safety-information-11550709442?mod=pls_whats_news_us_business_f Feb 20, 2019 - Johnson & Johnson said it received subpoenas from the Justice Department and the Securities and Exchange Commission seeking documents related to the safety of its baby powder and other talc-containing products.
Johnson & Johnson (JNJ) to Acquire Auris Health for $3.4B http://www.zacks.com/stock/news/354868/johnson-johnson-jnj-to-acquire-auris-health-for-%2434b?cid=CS-ZC-FT-354868 Feb 14, 2019 - Johnson & Johnson (JNJ) entered into a definitive agreement to acquire Auris Health, Inc., a developer of robotic technologies focused on lung cancer, for approximately $3.4 billion in cash.
Flip the Script: Drugmakers Blame Middlemen for Price Increases https://www.wsj.com/articles/flip-the-script-drugmakers-blame-middlemen-for-price-hikes-11549364401?mod=pls_whats_news_us_business_f Feb 05, 2019 - Under pressure over rising drug prices, pharmaceutical companies are pushing a new defense: They’re not raising prices to make money or to cover research costs, but rather to pay a cut to middlemen in the supply chain.
Roche Halts Two Late-Stage Studies on Alzheimer's Candidate http://www.zacks.com/stock/news/350873/roche-halts-two-late-stage-studies-on-alzheimers-candidate?cid=CS-ZC-FT-350873 Jan 30, 2019 - Roche (RHHBY) discontinues two phase III studies evaluating its anti-beta-amyloid molecule, crenezumab in people with early sporadic Alzheimer's disease.
3 Big Pharmas Expecting a Softer 2019 https://www.fool.com/investing/2019/01/30/3-big-pharmas-expecting-a-softer-2019.aspx?source=iedfolrf0000001 Jan 30, 2019 - Here's why some of the industry's largest players are telling investors not to expect any fireworks this year.

Pages: 1...345678910111213...107

<<<Page 8>